Evidence map›Paper›PMID 32767735›Full record

ArticleDiagnostic cytopathology2020

Multiplatform molecular test performance in indeterminate thyroid nodules.

Mark A Lupo, Ann E Walts, J Woody Sistrunk, Thomas J Giordano, Peter M Sadow, Nicole Massoll, Ryan Campbell, Sara A Jackson, Nicole Toney, Christina M Narick and 4 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic cytopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Diagnostic utility ofEXCLI journal · 2024
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Mark A LupoThyroid & Endocrine Center of Florida, Sarasota, Florida, USA.
Ann E WaltsCedars-Sinai Medical Center, Los Angeles, California, USA.
J Woody SistrunkJackson Thyroid & Endocrine Clinic, Jackson, Mississippi, USA.
Thomas J GiordanoUniversity of Michigan, Ann Arbor, Michigan, USA.
Peter M SadowMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Nicole MassollUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Ryan CampbellUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Sara A JacksonInterpace Diagnostics, Parsippany, New Jersey, USA.
Nicole ToneyInterpace Diagnostics, Parsippany, New Jersey, USA.ORCID https://orcid.org/0000-0002-7893-0377
Christina M NarickInterpace Diagnostics, Parsippany, New Jersey, USA.
Gyanendra KumarInterpace Diagnostics, Parsippany, New Jersey, USA.
Alidad MireskandariInterpace Diagnostics, Parsippany, New Jersey, USA.
Sydney D FinkelsteinInterpace Diagnostics, Parsippany, New Jersey, USA.
Shikha BoseCedars-Sinai Medical Center, Los Angeles, California, USA.
Medpace (United States) · USCedars-Sinai Medical Center · USUniversity of Arkansas for Medical Sciences · USHarvard University · USJackson Memorial Hospital · USUniversity of Michigan · USUniversity of South Florida Sarasota–Manatee · US

Funding

Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI MEMPEL, THORSTEN ROMAN · 2019 to 2023
$8.4M
Interpace DiagnosticsNCI NIH HHS P01 CA240239
6 · The paper itself

Abstract

backgroundApproximately 25% of thyroid nodule fine-needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Accurate risk stratification of these FNAs with ancillary testing would reduce unnecessary thyroid surgery.

methodsWe evaluated the performance of an ancillary multiplatform test (MPTX) that has three diagnostic categories (negative, moderate, and positive). MPTX includes the combination of a mutation panel (ThyGeNEXT®) and a microRNA risk classifier (ThyraMIR®). A blinded, multicenter study was performed using consensus histopathology diagnosis among three pathologists to validate test performance.

resultsUnanimous consensus diagnosis was reached in 197 subjects with indeterminate thyroid nodules; 36% had disease. MPTX had 95% sensitivity (95% CI,86%-99%) and 90% specificity (95% CI,84%-95%) for disease in prevalence adjusted nodules with Bethesda III and IV cytology. Negative MPTX results ruledout disease with 97% negative predictive value (NPV; 95% CI,91%-99%) at a 30% disease prevalence, while positive MPTX results ruledin high risk disease with 75% positive predictive value (PPV; 95% CI,60%-86%). Such results are expected in four out of five Bethesda III and IV nodules tested, including RAS positive nodules in which the microRNA classifier was useful in rulingin disease. 90% of mutation panel false positives were due to analytically verified RAS mutations detected in benign adenomas. Moderate MPTX results had a moderate rate of disease (39%, 95% CI,23%-54%), primarily due to RAS mutations, wherein the possibility of disease could not be excluded.

conclusionsOur results emphasize that decisions for surgery should not solely be based on RAS or RAS-like mutations. MPTX informs management decisions while accounting for these challenges.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBiopsy, Fine-NeedleFemaleHumansMaleMicroRNAsMiddle AgedMutationPredictive Value of TestsRetrospective StudiesSensitivity and SpecificityThyroid GlandThyroid NeoplasmsBiomarkers, TumorMicroRNAsindeterminate thyroid nodulesmalignancymolecular testoutcomes

Identifiers

PMID32767735
PMCPMC7754490
OpenAlexW3048164757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.